CP-547,632

DRUG3 trials

Sponsors

Pfizer, Jonsson Comprehensive Cancer Center

Conditions

Fallopian Tube CancerFallopian Tube NeoplasmsLung NeoplasmsOvarian CancerOvarian NeoplasmsPeritoneal NeoplasmsPrimary Peritoneal Cavity Cancer

Phase 1

A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

CompletedNCT00074854

PfizerLung Neoplasms

Start: 2002-05-31End: 2005-03-31Target: 87Updated: 2006-11-09

Phase 2

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

CompletedNCT00074867

PfizerFallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Start: 2003-10-31End: 2004-09-30Target: 29Updated: 2006-11-07

CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

CompletedNCT00096239

Jonsson Comprehensive Cancer CenterFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

Start: 2004-12-31End: 2005-02-28Updated: 2013-12-19